bcl-2 and MIB-1 labeling indexes in cats with lymphoma

Journal of Veterinary Internal Medicine

Volumn 16, Issue 6, 2002, Pages 720-725

  Dank, Gillian ^a   Lucroy, Michael D ^c   Griffey, Stephen M ^a   Gandour Edwards, Regina ^b   Madewell, Bruce R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Cellular proliferation; Feline

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINUCLEAR ANTIBODY; MIB 1 ANTIBODY; MIB-1 ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN BCL 2;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOSYNTHESIS; CAT; CAT DISEASE; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOMA; MALE; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAT DISEASES; CATS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL; TREATMENT OUTCOME;

EID: 0036835837     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2002.tb02414.x     Document Type: Article

References (28)

1. Mooney, SC, Hayes AA, MacEwen EG, et al. Treatment and prognostic factors for lymphoma in cats: 103 cases (1977-1981). J Am Vet Med Assoc 1989;194:696-702.
2. Ogilvie GK, Moore AS. Managing the veterinary cancer patient. Trenton, NJ: Veterinary Learning Systems; 1995:249-255
3. Gabor LJ, Canfield PJ, Malik R. Immunophenotypic and histological characterization of 109 cases of feline lymphosarcoma. Aust Vet J 1999;77:436-441.
4. Vail DM, Moore AS, Ogilvie GK, et al. Feline lymphoma (145 cases): Proliferation indices, cluster of differentiation 3 immunoreactivity, and their association with prognosis in the cat. J Vet Intern Med 1998;12.349-354.
5. Rassnick KM, Mauldin GN, Moroff SD, et al. Prognostic value of argyrophilic nucleolar organizer region (AgNOR) staining in feline intestinal lymphoma. J Vet Intern Med 1999;13:187-190
6. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy Blood 1997;89:1845-1853.
7. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187:127-137.
8. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National lymphoma investigation study. Blood 1996;88:1046-1051.
9. Madewell BR, Gandour-Edwards R, Edwards BF, et al. Topographic distribution of bcl-2 protein in feline tissues in health and neoplasia. Vet Pathol 1999;36:565-573.
10. Brown DC, Gatter KC. Ki167 protein: The immaculate deception? Histopathol 2001;40 2-11.
11. Zwahlen CH, Kraegel SA, Lucroy MD, et al. Results of chemotherapy in cats with alimentary malignant lymphoma: 21 cases (1993-1997). J Am Vet Med Assoc 1998;213:1144-1149.
12. Rosenberg SA, Berard CW, Brown BW, et al. National Cancer Institute study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
13. Valli VEO. The hematopoietic system. In: Jubb KVF, Kennedy PC, Palmer N, eds Pathology of Domestic Animals, 4th ed. San Diego, CA: Academic Press: 1993:138-157.
14. Kaplan EL, Meier MP. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Fleming TR, Harrington DP. A class of hypothesis tests for one and two sampled censored survival data. Commun Stat 1981; A210: 763-794.
16. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992;80:879-886.
17. Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-1443.
18. Zutter H, Hockenberry D, Silverman GA, et al. Immunolocalization of the bcl-2 protein within hematopoietic neoplasms. Blood 1991;78:1062-1068.
19. Gaulard P, d'Agay MF, Peuchmaur M, et al. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 1992;140: 1089-1095.
20. MacCarthy-Morrogh L, Mouzakiti A, Townsend P, et al. Bcl-2 proteins and cancer. Biochem Soc Trans 1999;27:785-789.
21. Vaux DL, Cory S, Adams JM. Bcl-2 promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442.
22. Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest 1999;104:1655-1661.
23. Reed JC. Mini-review: Cellular mechanisms of disease series. Bcl-2 and its regulation of programmed cell death. J Cell Biol 1994; 124:1-6.
24. Onions D, Lees G, Forrest D, et al. Recombinant feline viruses containing the myc gene rapidly produce clonal tumours expressing T-cell antigen receptor gene transcripts. Int J Cancer 1987;40:40-45.
25. Yunis JJ, Mayer MG, Arensen MA, et al. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphomas. N Engl J Med 1989;320:1047-1054.
26. Leonincini L, del Vecchio MT, Spina D, et al. Presence of the bcl-2 protein and apoptosis in non-Hodgkin lymphomas with diffuse growth patterns. Int J Cancer 1995;61:826-831.
27. Shinoura N, Yoshida Y, Nishimura M, et al. Expression level of Bcl-2 determines anti- or proapoptotic function. Cancer Res 1999; 59:4119-4128.
28. Kip-1 in feline lymphoma. Vet Pathol 2001;38:698-702.